IGHV2-70

Across TCGA pan-cancer cohorts, IGHV2-70 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of IGHV2-70’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where IGHV2-70 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types IGHV2-70 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, LUAD, and PDAC are the cancer types where IGHV2-70 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGHV2-70 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	All	−1.049	<.001	8	view →
LUAD	Male	All	−0.617	<.001	5	view →
PDAC	All	All	+0.909	.001	4	view →
LSCC	Male	All	−0.473	<.001	4	view →
OV	All	All	−2.173	.007	2	view →
CCRCC	All	All	+0.414	.013	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

IGHV2-70–HNSC

Open the HNSC breakdown →